The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding ... to discontinue Levemir, a long-acting insulin, "failed to take ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
An FDA advisory committee mostly agreed on Friday that an investigational once-weekly insulin product carries too much risk for use in adult patients with type 1 diabetes to recommend approval in ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.